This content is for members only
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reported impressive results on December 1, 2018 for its lymphoma drug candidate Selinexor, noting patients who experienced a complete or partial response in a 125-patient trial had a median overall survival rate of 29.7 months. Previously published […]
Last week, Galmed Pharmaceuticals (NASDAQ:GLMD) shares climbed as high as $9.90 per share this week, up approximately 7% on the day after the company released updated phase IIb results for Aramchol, the company’s treatment for NASH (non-alcoholic steatohepatitis). Galmed reported […]
This content is for members only
This content is for members only
This content is for members only
Because FDA marketing clearance to sell a drug or device in the US remains the brass ring for medical manufacturers around the world, companies consistently invested in US trials in spite of rising costs. By 2016, however, more manufacturers were […]
Introducing SanaCurrents Introducing SanaCurrents, a research service for the serious and sophisticated biotech investor. Founder of SanaCurrents, Bill Langbein, finally brings his service to the mainstream to enable biotech investors to track catalysts through the lens of varying levels of […]